Immunogenicity and Safety of a Combined Intramuscular/Intranasal Recombinant Spike Protein COVID-19 Vaccine (RCP) in Healthy Adults Aged 18 to 55 Years Old: A Randomized, Double-Blind, Placebo-Controlled, Phase I Trial

Objectives: This study aimed to determine the safety and immunogenicity of a combined intramuscular/intranasal recombinant spike protein COVID-19 vaccine (RCP). Methods: We conducted a randomized, double-blind, placebo-controlled, phase I trial. Three vaccine strengths were compared with an adjuvant...

Descripción completa

Detalles Bibliográficos
Autores principales: Dodaran, Masoud Solaymani, Banihashemi, Seyed Reza, Es-haghi, Ali, Mehrabadi, Mohammad Hossein Fallah, Nofeli, Mojtaba, Mokarram, Ali Rezaei, Mokhberalsafa, Ladan, Sadeghi, Fariba, Ranjbar, Alireza, Ansarifar, Akram, Mohazzab, Arash, Setarehdan, Seyed Amin, Bagheri Amiri, Fahimeh, Mohseni, Vahideh, Hajimoradi, Monireh, Ghahremanzadeh, Neda, Razzaz, Seyed Hossein, Masoomi, Safdar, Taghdiri, Maryam, Bagheri, Mohsen, Lofti, Mohsen, Khorasani, Akbar, Ghader, Masoud, Safari, Shiva, Shahsavn, Masumeh, Kalantari, Saeed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961243/
https://www.ncbi.nlm.nih.gov/pubmed/36851334
http://dx.doi.org/10.3390/vaccines11020455

Ejemplares similares

Ejemplares similares